New Considerations for Oligometastatic Prostate Cancer

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, presented “New Considerations for Oligometastatic Prostate Cancer” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.

How to cite: Concepcion, Raoul S. “New Considerations for Oligometastatic Prostate Cancer” January 26, 2019. Accessed Oct 2026. https://grandroundsinurology.com/new-considerations-for-oligometastatic-prostate-cancer-2/

New Considerations for Oligometastatic Prostate Cancer – Summary:

Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic. Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival. Also, physicians must take into consideration patients presenting with synchronous or metachronous lesions, the location of their disease (bone, nodal or visceral), and whether or not they are hormone-naïve versus castration-resistant. Increasing utilization of biomolecular/next generation imaging will surely compound the issue, due to the increased sensitivity of these scans relative to traditional staging modalities. In this presentation, Dr. Concepcion highlights these issues and reviews the current status of this challenging, evolving patient population.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Concepcion presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.

ABOUT THE AUTHOR

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society.

About The Author

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society. Dr. Concepcion completed his residency in general surgery and urology at Vanderbilt University in Nashville, Tennessee, where he was Chief Urology Resident, and later served as a Clinical Associate Professor of Urology. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed the City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. Dr. Concepcion has been in practice since 1990 and has been the principal or co-principal investigator on many clinical trials since then. His clinical interests focus on advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. Dr. Concepcion co-founded CUSP, a urologic research consortium in the United States that specializes in site and patient accrual for the pharmaceutical and biolab industries. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.

Share This